Caixin Global – Latest China News & Headlines

Home >


CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

Shanghai-Based Robot Developer Closes $46 Million Funding Round
Trending in China: Top Broadcast Exec Questions if Esports Are Really a Sport – Cue Heated Debate
Chinese Video Streamer iQiyi Targets U.S. Market With Animation on Nickelodeon
Chinese Majority Owned Lotus Announce EV Sports Car Venture With Renault’s Alpine
Chinese New Film Materials Maker HIUV on Track to Raise $227m in STAR Market IPO
Jordan Slam Dunks on Copycat Chinese Sportswear Brand Forcing Them to Change Their Name
Trending in China: Will ‘Chinese Baijiu’ Name Change Propel It To Global Dominance?
EHang Pioneers Self-Flying Drones for Tourists in Greater Bay Area City
TCL Squashes Rumours it is Withdrawing From North America Amid Empty Shelves
Chinese PE Fund Manager CICC Capital Secures $649m Second Close of Biomedicine Fund
WeRide Receives $310 Million as Beijing Opens Highways to Autonomous Car Tests
China’s Orchid Asia Leads Funding in Delivery Platform Fantuan, Edtech Startup Ivydad
U.S.-Listed Video Streamer Bilibili Files for Secondary Listing in Hong Kong, CNBC Reports
Dining Delivery Pay Dispute Leads Man to Set Himself on Fire
PayPal Becomes First Foreign Company to Offer Digital Payments in China
Tesla Rival Xpeng Motors Into New Year Fueled By New Credit Line
China’s Smartphone Shipments Fall Nearly 13% in December Amid Virus Flare-Up
Trending in China: Weibo Fails to See the ‘Funny Side’ of Sexual Harassment
Luxury Retailer Secoo Looks to Join Exodus of Chinese Companies from U.S. Stock Exchanges
Chinese Biotech Firm VISEN Raises $150m Led by Sequoia Capital China
Chinese PE Fund Manager CICC Capital Secures $649m Second Close of Biomedicine Fund

By DealStreetAsia / Jan 14, 2021 01:01 PM / Finance



CICC Capital, the private equity (PE) fund management platform of Hong Kong-listed investment bank CICC, has reached the second closing of its biomedicine fund at over 4.2 billion yuan ($648.7 million), said the firm in a WeChat post on Monday.

The new fund — whose name can be translated into “CICC Qide Innovation Biopharmaceutical Equity Investment Fund (CICC Qide)” in English — was oversubscribed by limited partners (LPs) including Chinese state-owned asset managers, China-based pharmaceutical companies, corporates in China and worldwide, other investment institutions, as well as CICC’s ultra-high-net-worth (UHNW) individual clients.

“COVID-19 has catalysed exponential growth of the health industry in the past one year. Sectors like vaccines, innovative medicines, and internet-based medical care have attracted abundant stimuli, such as technological innovations, consumer demand, and favourable policies to become the major focuses of the capital market, as well as the market’s main driving forces,” said CICC Capital.

The biomedicine fund had raised more than 1.6 billion yuan in its first closing in February 2020. At its launch in late 2019, the initial target for the first closing was 1.5 billion yuan.

The vehicle has already invested in over 20 startups with several portfolio companies entering the IPO process.

Last year, it co-led a Series D round of nearly 300 million yuan for San Diego-based clinical-stage biopharmaceutical firm Denovo Biopharma in December. In August, CICC Qide had participated in biopharmaceutical startup Sinovent’s 1-billion-yuan Series C round. It also invested in drugmaker CF PharmTech’s 360-million-yuan Series F round in July and Beijing-based Mabworks’ Series C1, C2 rounds, in which the firm pocketed a combined 1.13 billion yuan.

Among its portfolio companies is the clinical-stage oncology therapy developer Jacobio Pharmaceuticals Group, which completed an initial public offering (IPO) in Hong Kong in December 2020 and raised about HK$1.35 billion — only seven months after CICC Qide had made the investment. Also backed by Qiming Venture Partners and Hillhouse Capital, Jacobio saw the retail tranche of its IPO being oversubscribed by 298.6 times.

CICC Capital is the flagship platform of Beijing-based China International Capital Corporation (CICC) for its global private equity businesses. The firm manages RMB- and USD-denominated funds with various strategies including venture capital, growth, buyout, fund of funds (FOF), and distressed investments.

At the end of 2020, it employed more than 300 investment professionals and managed over 350 billion yuan ($54.1) in total assets under management (AUM).

Contact editor Marcus Ryder (

Related: Chinese Biotech Giant’s Stock Surges on Approvals for Genetically Modified Crops

Share this article
Open WeChat and scan the QR code